Breast Cancer - Pipeline Review, H1 2014


#196412

1724pages

Global Markets Direct

$ 2500

In Stock

 

This report provides comprehensive information on the therapeutic development for Breast Cancer,complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Breast Cancer 
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Breast Cancerproducts under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer 
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Content

 

 

Table of Contents 2
Introduction 12
Breast Cancer Overview 13
Therapeutics Development 14
Breast Cancer - Therapeutics under Development by Companies 16
Breast Cancer - Therapeutics under Investigation by Universities/Institutes 39
Breast Cancer - Pipeline Products Glance 48
Breast Cancer - Products under Development by Companies 52
Breast Cancer - Products under Investigation by Universities/Institutes 83
Breast Cancer - Companies Involved in Therapeutics Development 94
Breast Cancer - Therapeutics Assessment 363
Drug Profiles 409
Breast Cancer - Recent Pipeline Updates 1314
Breast Cancer - Dormant Projects 1619
Breast Cancer - Discontinued Products 1643
Breast Cancer - Product Development Milestones 1648
 

Appendix 1655

 

Number of Products under Development for Breast Cancer, H1 2014 82

Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2014 83

Number of Products under Development by Companies, H1 2014 85

Number of Products under Development by Companies, H1 2014 (Contd..1) 86

Number of Products under Development by Companies, H1 2014 (Contd..2) 87

Number of Products under Development by Companies, H1 2014 (Contd..3) 88

Number of Products under Development by Companies, H1 2014 (Contd..4) 89

Number of Products under Development by Companies, H1 2014 (Contd..5) 90

Number of Products under Development by Companies, H1 2014 (Contd..6) 91

Number of Products under Development by Companies, H1 2014 (Contd..7) 92

Number of Products under Development by Companies, H1 2014 (Contd..8) 93

Number of Products under Development by Companies, H1 2014 (Contd..9) 94

Number of Products under Development by Companies, H1 2014 (Contd..10) 95

Number of Products under Development by Companies, H1 2014 (Contd..11) 96

Number of Products under Development by Companies, H1 2014 (Contd..12) 97

Number of Products under Development by Companies, H1 2014 (Contd..13) 98

Number of Products under Development by Companies, H1 2014 (Contd..14) 99

Number of Products under Development by Companies, H1 2014 (Contd..15) 100

Number of Products under Development by Companies, H1 2014 (Contd..16) 101

Number of Products under Development by Companies, H1 2014 (Contd..17) 102

Number of Products under Development by Companies, H1 2014 (Contd..18) 103

Number of Products under Development by Companies, H1 2014 (Contd..19) 104

Number of Products under Development by Companies, H1 2014 (Contd..20) 105

Number of Products under Development by Companies, H1 2014 (Contd..21) 106

Number of Products under Investigation by Universities/Institutes, H1 2014 108

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 109

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 110

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 111

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 112

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 113

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 114

Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..7) 115

Comparative Analysis by Late Stage Development, H1 2014 116

Comparative Analysis by Clinical Stage Development, H1 2014 117

Comparative Analysis by Early Stage Development, H1 2014 118

Comparative Analysis by Unknown Stage Development, H1 2014 119

Products under Development by Companies, H1 2014 120

Products under Development by Companies, H1 2014 (Contd..1) 121

Products under Development by Companies, H1 2014 (Contd..2) 122

Products under Development by Companies, H1 2014 (Contd..3) 123

Products under Development by Companies, H1 2014 (Contd..4) 124

Products under Development by Companies, H1 2014 (Contd..5) 125

Products under Development by Companies, H1 2014 (Contd..6) 126

Products under Development by Companies, H1 2014 (Contd..7) 127

Products under Development by Companies, H1 2014 (Contd..8) 128

Products under Development by Companies, H1 2014 (Contd..9) 129

Products under Development by Companies, H1 2014 (Contd..10) 130

Products under Development by Companies, H1 2014 (Contd..11) 131

Products under Development by Companies, H1 2014 (Contd..12) 132

Products under Development by Companies, H1 2014 (Contd..13) 133

Products under Development by Companies, H1 2014 (Contd..14) 134

Products under Development by Companies, H1 2014 (Contd..15) 135

Products under Development by Companies, H1 2014 (Contd..16) 136

Products under Development by Companies, H1 2014 (Contd..17) 137

Products under Development by Companies, H1 2014 (Contd..18) 138

Products under Development by Companies, H1 2014 (Contd..19) 139

Products under Development by Companies, H1 2014 (Contd..20) 140

Products under Development by Companies, H1 2014 (Contd..21) 141

Products under Development by Companies, H1 2014 (Contd..22) 142

Products under Development by Companies, H1 2014 (Contd..23) 143

Products under Development by Companies, H1 2014 (Contd..24) 144

Products under Development by Companies, H1 2014 (Contd..25) 145

Products under Development by Companies, H1 2014 (Contd..26) 146

Products under Development by Companies, H1 2014 (Contd..27) 147

Products under Development by Companies, H1 2014 (Contd..28) 148

Products under Development by Companies, H1 2014 (Contd..29) 149

Products under Development by Companies, H1 2014 (Contd..30) 150

Products under Investigation by Universities/Institutes, H1 2014 151

Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 152

Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 153

Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 154

Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 155

Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 156

Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 157

Products under Investigation by Universities/Institutes, H1 2014 (Contd..7) 158

Products under Investigation by Universities/Institutes, H1 2014 (Contd..8) 159

Products under Investigation by Universities/Institutes, H1 2014 (Contd..9) 160

Products under Investigation by Universities/Institutes, H1 2014 (Contd..10) 161

Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 162

Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 163

Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 164

Breast Cancer - Pipeline by Celsion Corporation, H1 2014 165

Breast Cancer - Pipeline by Amgen Inc., H1 2014 166

Breast Cancer - Pipeline by Sanofi, H1 2014 167

Breast Cancer - Pipeline by AstraZeneca PLC, H1 2014 168

Breast Cancer - Pipeline by Eli Lilly and Company, H1 2014 169

Breast Cancer - Pipeline by Viralytics Ltd., H1 2014 170

Breast Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 171

Breast Cancer - Pipeline by Bioniche Life Sciences, Inc., H1 2014 172

Breast Cancer - Pipeline by Genentech, Inc., H1 2014 173

Breast Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 174

Breast Cancer - Pipeline by MedImmune, LLC, H1 2014 175

Breast Cancer - Pipeline by Biotest AG, H1 2014 176

Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 177

Breast Cancer - Pipeline by Merck & Co., Inc., H1 2014 178

Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2014 179

Breast Cancer - Pipeline by Generex Biotechnology Corporation, H1 2014 180

Breast Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 181

Breast Cancer - Pipeline by Ipsen S.A., H1 2014 182

Breast Cancer - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 183

Breast Cancer - Pipeline by MediGene AG, H1 2014 184

Breast Cancer - Pipeline by Celltrion, Inc., H1 2014 185

Breast Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2014 186

Breast Cancer - Pipeline by Histogen, Inc., H1 2014 187

Breast Cancer - Pipeline by Egenix, Inc., H1 2014 188

Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 189

Breast Cancer - Pipeline by Hanwha Chemical Corporation, H1 2014 190

Breast Cancer - Pipeline by Novartis AG, H1 2014 191

Breast Cancer - Pipeline by Samyang Holdings Corporation, H1 2014 192

Breast Cancer - Pipeline by Aphios Corporation, H1 2014 193

Breast Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 194

Breast Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 195

Breast Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 196

Breast Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 197

Breast Cancer - Pipeline by Eisai Co., Ltd., H1 2014 198

Breast Cancer - Pipeline by Richter Gedeon Nyrt., H1 2014 199

Breast Cancer - Pipeline by rEVO Biologics, H1 2014 200

Breast Cancer - Pipeline by GTx, Inc., H1 2014 201

Breast Cancer - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 202

Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2014 203

Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 204

Breast Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 205

Breast Cancer - Pipeline by Pfizer Inc., H1 2014 206

Breast Cancer - Pipeline by Sigma-Tau S.p.A., H1 2014 207

Breast Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 208

Breast Cancer - Pipeline by Takara Holdings Inc., H1 2014 209

Breast Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 210

Breast Cancer - Pipeline by Sandoz Inc., H1 2014 211

Breast Cancer - Pipeline by Exelixis, Inc., H1 2014 212

Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 213

Breast Cancer - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 214

Breast Cancer - Pipeline by CEL-SCI Corporation, H1 2014 215

Breast Cancer - Pipeline by Celgene Corporation, H1 2014 216

Breast Cancer - Pipeline by Bayer AG, H1 2014 217

Breast Cancer - Pipeline by AntiCancer, Inc., H1 2014 218

Breast Cancer - Pipeline by Incyte Corporation, H1 2014 219

Breast Cancer - Pipeline by Advaxis, Inc., H1 2014 220

Breast Cancer - Pipeline by Alchemia Limited, H1 2014 221

Breast Cancer - Pipeline by EntreMed, Inc., H1 2014 222

Breast Cancer - Pipeline by GW Pharmaceuticals plc, H1 2014 223

Breast Cancer - Pipeline by Harbor Therapeutics, Inc., H1 2014 224

Breast Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H1 2014 225

Breast Cancer - Pipeline by ValiRx Plc, H1 2014 226

Breast Cancer - Pipeline by AEterna Zentaris Inc., H1 2014 227

Breast Cancer - Pipeline by Immunomedics, Inc., H1 2014 228

Breast Cancer - Pipeline by Genfit SA, H1 2014 229

Breast Cancer - Pipeline by Lorus Therapeutics Inc., H1 2014 230

Breast Cancer - Pipeline by MEI Pharma, Inc., H1 2014 231

Breast Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2014 232

Breast Cancer - Pipeline by Bionomics Limited, H1 2014 233

Breast Cancer - Pipeline by MultiCell Technologies, Inc., H1 2014 234

Breast Cancer - Pipeline by Compugen Ltd., H1 2014 235

Breast Cancer - Pipeline by Patrys Limited, H1 2014 236

Breast Cancer - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2014 237

Breast Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 238

Breast Cancer - Pipeline by Medivation, Inc., H1 2014 239

Breast Cancer - Pipeline by Mast Therapeutics, Inc., H1 2014 240

Breast Cancer - Pipeline by Telik, Inc., H1 2014 241

Breast Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 242

Breast Cancer - Pipeline by Repros Therapeutics Inc., H1 2014 243

Breast Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2014 244

Breast Cancer - Pipeline by Dendreon Corporation, H1 2014 245

Breast Cancer - Pipeline by ProMetic Life Sciences Inc., H1 2014 246

Breast Cancer - Pipeline by Progen Pharmaceuticals Limited, H1 2014 247

Breast Cancer - Pipeline by TapImmune Inc., H1 2014 248

Breast Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2014 249

Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 250

Breast Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2014 251

Breast Cancer - Pipeline by Galapagos NV, H1 2014 252

Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 253

Breast Cancer - Pipeline by Panacea Biotec Limited, H1 2014 254

Breast Cancer - Pipeline by Sareum Holdings plc, H1 2014 255

Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014 256

Breast Cancer - Pipeline by Algeta ASA, H1 2014 257

Breast Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2014 258

Breast Cancer - Pipeline by Galena Biopharma, Inc., H1 2014 259

Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2014 260

Breast Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014 261

Breast Cancer - Pipeline by Merrion Pharmaceuticals Plc, H1 2014 262

Breast Cancer - Pipeline by Scancell Holdings Plc, H1 2014 263

Breast Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014 264

Breast Cancer - Pipeline by Nanobiotix SA, H1 2014 265

Breast Cancer - Pipeline by Antigen Express, Inc., H1 2014 266

Breast Cancer - Pipeline by Morphotek, Inc., H1 2014 267

Breast Cancer - Pipeline by Oryzon Genomics S.A., H1 2014 268

Breast Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 269

Breast Cancer - Pipeline by Debiopharm International S.A., H1 2014 270

Breast Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2014 271

Breast Cancer - Pipeline by CIMAB S.A., H1 2014 272

Breast Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 273

Breast Cancer - Pipeline by Supratek Pharma Inc., H1 2014 274

Breast Cancer - Pipeline by Meabco A/S, H1 2014 275

Breast Cancer - Pipeline by Biotecnol Limited, H1 2014 276

Breast Cancer - Pipeline by Fusion Antibodies Ltd, H1 2014 277

Breast Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2014 278

Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 279

Breast Cancer - Pipeline by Philogen S.p.A., H1 2014 280

Breast Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2014 281

Breast Cancer - Pipeline by Quantum Pharmaceuticals, H1 2014 282

Breast Cancer - Pipeline by Multimmune GmbH, H1 2014 283

Breast Cancer - Pipeline by Med Discovery SA, H1 2014 284

Breast Cancer - Pipeline by Glycotope GmbH, H1 2014 285

Breast Cancer - Pipeline by TheRyte Ltd., H1 2014 286

Breast Cancer - Pipeline by Priaxon AG, H1 2014 287

Breast Cancer - Pipeline by Hutchison MediPharma Limited, H1 2014 288

Breast Cancer - Pipeline by Vaxon Biotech, H1 2014 289

Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2014 290

Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2014 291

Breast Cancer - Pipeline by GenSpera, Inc., H1 2014 292

Breast Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2014 293

Breast Cancer - Pipeline by Coronado Biosciences, Inc., H1 2014 294

Breast Cancer - Pipeline by Heat Biologics, Inc., H1 2014 295

Breast Cancer - Pipeline by MacroGenics, Inc., H1 2014 296

Breast Cancer - Pipeline by Antyra, Inc., H1 2014 297

Breast Cancer - Pipeline by Ambrx, Inc., H1 2014 298

Breast Cancer - Pipeline by Arno Therapeutics, Inc., H1 2014 299

Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 300

Breast Cancer - Pipeline by Kalos Therapeutics, Inc., H1 2014 301

Breast Cancer - Pipeline by Vaccinex, Inc., H1 2014 302

Breast Cancer - Pipeline by Pantarhei Bioscience BV, H1 2014 303

Breast Cancer - Pipeline by AlphaVax, Inc., H1 2014 304

Breast Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2014 305

Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 306

Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2014 307

Breast Cancer - Pipeline by Conatus Pharmaceuticals Inc., H1 2014 308

Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 309

Breast Cancer - Pipeline by Angion Biomedica Corp., H1 2014 310

Breast Cancer - Pipeline by Affichem, H1 2014 311

Breast Cancer - Pipeline by Jennerex Biotherapeutics, Inc., H1 2014 312

Breast Cancer - Pipeline by Axelar AB, H1 2014 313

Breast Cancer - Pipeline by Endocyte, Inc., H1 2014 314

Breast Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2014 315

Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2014 316

Breast Cancer - Pipeline by Pharminox Limited, H1 2014 317

Breast Cancer - Pipeline by Thrasos, Inc., H1 2014 318

Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 319

Breast Cancer - Pipeline by Immunotope, Inc., H1 2014 320

Breast Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 321

Breast Cancer - Pipeline by TransTech Pharma, Inc., H1 2014 322

Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2014 323

Breast Cancer - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2014 324

Breast Cancer - Pipeline by Immunovaccine, Inc., H1 2014 325

Breast Cancer - Pipeline by Welichem Biotech Inc., H1 2014 326

Breast Cancer - Pipeline by Etubics Corporation, H1 2014 327

Breast Cancer - Pipeline by Immune Design Corp., H1 2014 328

Breast Cancer - Pipeline by NewLink Genetics Corporation, H1 2014 329

Breast Cancer - Pipeline by Seek, H1 2014 330

Breast Cancer - Pipeline by Cellceutix Corporation, H1 2014 331

Breast Cancer - Pipeline by Xcovery, Inc., H1 2014 332

Breast Cancer - Pipeline by Pharma Mar, S.A., H1 2014 333

Breast Cancer - Pipeline by TVAX Biomedical, Inc., H1 2014 334

Breast Cancer - Pipeline by Quintessence Biosciences, Inc., H1 2014 335

Breast Cancer - Pipeline by Sirnaomics, Inc., H1 2014 336

Breast Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 337

Breast Cancer - Pipeline by to-BBB technologies BV, H1 2014 338

Breast Cancer - Pipeline by Genelux Corporation, H1 2014 339

Breast Cancer - Pipeline by GlycoMimetics, Inc., H1 2014 340

Breast Cancer - Pipeline by Viventia Biotechnologies Inc., H1 2014 341

Breast Cancer - Pipeline by Oncovir, Inc., H1 2014 342

Breast Cancer - Pipeline by Nexgenix Pharmaceuticals, LLC, H1 2014 343

Breast Cancer - Pipeline by ViroMed Co., Ltd., H1 2014 344

Breast Cancer - Pipeline by Keystone Nano, Inc., H1 2014 345

Breast Cancer - Pipeline by EndoCeutics, Inc., H1 2014 346

Breast Cancer - Pipeline by biOasis Technologies Inc., H1 2014 347

Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2014 348

Breast Cancer - Pipeline by Zymeworks Inc., H1 2014 349

Breast Cancer - Pipeline by Domainex Ltd., H1 2014 350

Breast Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 351

Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2014 352

Breast Cancer - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2014 353

Breast Cancer - Pipeline by Oncolix, Inc., H1 2014 354

Breast Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014 355

Breast Cancer - Pipeline by EpiZyme, Inc., H1 2014 356

Breast Cancer - Pipeline by Sunshine Biopharma, Inc., H1 2014 357

Breast Cancer - Pipeline by Soricimed Biopharma Inc., H1 2014 358

Breast Cancer - Pipeline by Recepta Biopharma S.A., H1 2014 359

Breast Cancer - Pipeline by ISU ABXIS Co.,Ltd., H1 2014 360

Breast Cancer - Pipeline by Bioo Therapeutics, H1 2014 361

Breast Cancer - Pipeline by Molecular Templates Inc., H1 2014 362

Breast Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2014 363

Breast Cancer - Pipeline by Almac Discovery Ltd., H1 2014 364

Breast Cancer - Pipeline by Recombio, H1 2014 365

Breast Cancer - Pipeline by NuCana BioMed Limited, H1 2014 366

Breast Cancer - Pipeline by f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H, H1 2014 367

Breast Cancer - Pipeline by BHR Pharma, LLC, H1 2014 368

Breast Cancer - Pipeline by Pacific Northwest Biotechnology, LLC, H1 2014 369

Breast Cancer - Pipeline by Nuvilex, Inc., H1 2014 370

Breast Cancer - Pipeline by Incuron, LLC, H1 2014 371

Breast Cancer - Pipeline by Terpenoid Therapeutics, Inc., H1 2014 372

Breast Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2014 373

Breast Cancer - Pipeline by Plantacor, Inc., H1 2014 374

Breast Cancer - Pipeline by Pharmicell Co., Ltd., H1 2014 375

Breast Cancer - Pipeline by BiOrion Technologies B.V., H1 2014 376

Breast Cancer - Pipeline by DEKK-TEC, Inc., H1 2014 377

Breast Cancer - Pipeline by Regulon Inc., H1 2014 378

Breast Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2014 379

Breast Cancer - Pipeline by Laboratorio Elea S.A.C.I.F. and A, H1 2014 380

Breast Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H1 2014 381

Breast Cancer - Pipeline by Mabion SA, H1 2014 382

Breast Cancer - Pipeline by Miami VA Healthcare System, H1 2014 383

Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 384

Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2014 385

Breast Cancer - Pipeline by PT Dexa Medica, H1 2014 386

Breast Cancer - Pipeline by Wuxi MTLH Biotechnology Co. Ltd., H1 2014 387

Breast Cancer - Pipeline by Igenica, Inc., H1 2014 388

Breast Cancer - Pipeline by Immunophotonics Inc, H1 2014 389

Breast Cancer - Pipeline by ElexoPharm GmbH, H1 2014 390

Breast Cancer - Pipeline by Trojantec ltd., H1 2014 391

Breast Cancer - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 392

Breast Cancer - Pipeline by Verastem, Inc., H1 2014 393

Breast Cancer - Pipeline by Cold Genesys, Inc., H1 2014 394

Breast Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2014 395

Breast Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 396

Breast Cancer - Pipeline by Kancera AB, H1 2014 397

Breast Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014 398

Breast Cancer - Pipeline by Vaxeal Holding SA, H1 2014 399

Breast Cancer - Pipeline by Orega Biotech SAS, H1 2014 400

Breast Cancer - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2014 401

Breast Cancer - Pipeline by Conkwest, Inc., H1 2014 402

Breast Cancer - Pipeline by Pharma Two B Ltd, H1 2014 403

Breast Cancer - Pipeline by Laurantis Pharma Oy, H1 2014 404

Breast Cancer - Pipeline by Visionary Pharmaceuticals, Inc., H1 2014 405

Breast Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 406

Breast Cancer - Pipeline by Qu Biologics Inc., H1 2014 407

Breast Cancer - Pipeline by Oncobiologics, Inc., H1 2014 408

Breast Cancer - Pipeline by CZ BioMed Corp, H1 2014 409

Breast Cancer - Pipeline by Mission Therapeutics Ltd, H1 2014 410

Breast Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2014 411

Breast Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2014 412

Breast Cancer - Pipeline by Puma Biotechnology, Inc., H1 2014 413

Breast Cancer - Pipeline by Io Therapeutics, Inc., H1 2014 414

Breast Cancer - Pipeline by Avipep Pty Ltd, H1 2014 415

Breast Cancer - Pipeline by StemPar Sciences, Inc., H1 2014 416

Breast Cancer - Pipeline by Armour Therapeutics Inc., H1 2014 417

Breast Cancer - Pipeline by Oncomatrix, S.L., H1 2014 418

Breast Cancer - Pipeline by LondonPharma Ltd, H1 2014 419

Breast Cancer - Pipeline by AbbVie Inc., H1 2014 420

Breast Cancer - Pipeline by DormaTarg, Inc., H1 2014 421

Breast Cancer - Pipeline by Oncology Research International Limited, H1 2014 422

Breast Cancer - Pipeline by Oncbiomune, L.L.C., H1 2014 423

Breast Cancer - Pipeline by AlphaMab Co., Ltd, H1 2014 424

Breast Cancer - Pipeline by Vasgen Limited, H1 2014 425

Breast Cancer - Pipeline by MediaPharma s.r.l., H1 2014 426

Breast Cancer - Pipeline by Huabo Biopharm Co., Ltd., H1 2014 427

Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2014 428

Breast Cancer - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 429

Breast Cancer - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H1 2014 430

Assessment by Monotherapy Products, H1 2014 431

Assessment by Combination Products, H1 2014 432

Number of Products by Stage and Target, H1 2014 435

Number of Products by Stage and Mechanism of Action, H1 2014 453

Number of Products by Stage and Route of Administration, H1 2014 472

Number of Products by Stage and Molecule Type, H1 2014 475

Breast Cancer Therapeutics - Recent Pipeline Updates, H1 2014 1382

Breast Cancer - Dormant Projects, H1 2014 1687

Breast Cancer - Dormant Projects (Contd..1), H1 2014 1688

Breast Cancer - Dormant Projects (Contd..2), H1 2014 1689

Breast Cancer - Dormant Projects (Contd..3), H1 2014 1690

Breast Cancer - Dormant Projects (Contd..4), H1 2014 1691

Breast Cancer - Dormant Projects (Contd..5), H1 2014 1692

Breast Cancer - Dormant Projects (Contd..6), H1 2014 1693

Breast Cancer - Dormant Projects (Contd..7), H1 2014 1694

Breast Cancer - Dormant Projects (Contd..8), H1 2014 1695

Breast Cancer - Dormant Projects (Contd..9), H1 2014 1696

Breast Cancer - Dormant Projects (Contd..10), H1 2014 1697

Breast Cancer - Dormant Projects (Contd..11), H1 2014 1698

Breast Cancer - Dormant Projects (Contd..12), H1 2014 1699

Breast Cancer - Dormant Projects (Contd..13), H1 2014 1700

Breast Cancer - Dormant Projects (Contd..14), H1 2014 1701

Breast Cancer - Dormant Projects (Contd..15), H1 2014 1702

Breast Cancer - Dormant Projects (Contd..16), H1 2014 1703

Breast Cancer - Dormant Projects (Contd..17), H1 2014 1704

Breast Cancer - Dormant Projects (Contd..18), H1 2014 1705

Breast Cancer - Dormant Projects (Contd..19), H1 2014 1706

Breast Cancer - Dormant Projects (Contd..20), H1 2014 1707

Breast Cancer - Dormant Projects (Contd..21), H1 2014 1708

Breast Cancer - Dormant Projects (Contd..22), H1 2014 1709

Breast Cancer - Dormant Projects (Contd..23), H1 2014 1710

Breast Cancer - Discontinued Products, H1 2014 1711

Breast Cancer - Discontinued Products (Contd..1), H1 2014 1712

Breast Cancer - Discontinued Products (Contd..2), H1 2014 1713

Breast Cancer - Discontinued Products (Contd..3), H1 2014 1714

Breast Cancer - Discontinued Products (Contd..4), H1 2014 1715

 

Number of Products under Development for Breast Cancer, H1 2014 82

Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2014 83

Number of Products under Development by Companies, H1 2014 84

Number of Products under Investigation by Universities/Institutes, H1 2014 107

Comparative Analysis by Late Stage Development, H1 2014 116

Comparative Analysis by Clinical Stage Development, H1 2014 117

Comparative Analysis by Early Stage Products, H1 2014 118

Comparative Analysis by Unknown Stage Development, H1 2014 119

Assessment by Monotherapy Products, H1 2014 431

Assessment by Combination Products, H1 2014 432

Number of Products by Top 10 Target, H1 2014 433

Number of Products by Stage and Top 10 Target, H1 2014 434

Number of Products by Top 10 Mechanism of Action, H1 2014 451

Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 452

Number of Products by Top 10 Route of Administration, H1 2014 470

Number of Products by Stage and Top 10 Route of Administration, H1 2014 471

Number of Products by Top 10 Molecule Type, H1 2014 473

Number of Products by Stage and Top 10 Molecule Type, H1 2014 474